CMV-SEROPOSITIVE COLLATERAL DONORS SUPERIOR TO CMV-SERONEGATIVE DONORS TO IMPACT OUTCOMES OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (EHA 2026) - May 13, 2026 - Abstract #EHA-3854; PB4004; "Table 1 Transplant outcomes between CMV-seronegative donors and CMV-seropositive collateral donors in the pre-letermovir era and letermovir era the pre-letermovir era the pre-letermovir era letermovir era CMV-seronegative donors,n = 16 CMV-seropositive collateral donors, n = 58 P value CMV-seronegative donors,n = 27 CMV-seropositive collateral donors,n = 25 P value Neutrophil engraftment time, median95%CI +12(10−14) days +14(13−14) days 0.880 +12(11−13) days +14(13−15) days 0.001 Platelet engraftment time, median95%CI +21(13−29) days +16(13−19) days 0.408 +14(13−15) days +19(17−21) days 0.109 Refractory CMV viremia, n(%) 14(87.5%) 29(50.0%) 0.007 11(40.7%) 3(12.0%) 0.020 CMV disease, n(%) 4(25.0%) 6(10.3%) 0.129 2(7.4%) 5(20.0%) 0.184 3OS95%CI 75.0%53.8%−96.2% 80.0%68.6%−91.4% 0.479 88.3%75.8%−100.0% 76.4%58.0%−94.8% 0.622 3NRM95%CI 19.6%0%−39.6% 9.8%1.8%−17.8% 0.278 11.7%0%−24.2% 20.1%2.8%−37.4% 0.865 3CIR95%CI 6.7%0%−19.2% 19.8%8.0%−31.0% 0.291 11.8%0%−24.3%..."
Bone Marrow Transplantation • Cytomegalovirus Infection • Hematological Malignancies • Infectious Disease • Transplantation
|
|
Jing Liu 1; Yuan-Yuan Zhang 1; Xiao-Dong Mo 1; Yuqian Sun 1; Meng Lv 1; Xiaosu Zhao 1; Yifei Cheng 1; Haixia Fu 1; Lanping Xu 1; Xiaohui Zhang 1; Xiao-Jun Huang 1; Yu Wang1
|